USPTO 2015–2025 USPTO PatentsView US Corporation

IncellDx, Inc.

USPTO PatentsView assignee record - 14 granted patents across 12 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Incelldx ranks #19,896 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 12 technology areas.

#19,896
of 49,997 US assignees by volume
Top 45%
by Innovation Score (36.9/100)
14.4
avg claims per patent
+100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19896 · US Corporation #19,896 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,896/49,997
  • PHOTO-FINISH Ikena Oncology
  • CPC-FOCUS C12Q · 12 areas
  • INNOV-THIN 36.9/100
  • CLAIMS-RICH 14.4 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ikena Oncology, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Incelldx’s 36.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Incelldx

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Incelldx's Innovation Score is 36.9/100 (top 45% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Incelldx?

Each dot is one of Incelldx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Incelldx’s own 14.4 claims/patent is at or below the 19.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Incelldx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 510152025 Granted patents (volume) Avg claims / patent Ikena Oncology, Inc. - 14, 22.14Ikena OncologyImagine Scientific, Inc. - 14, 19.79Imagine ScientificImmutrix Therapeutics, Inc. - 14, 14.93Immutrix Therapeu…Implant Direct Sybron International LLC - 14, 10.14Implant Direct Sy…IneoQuesto Technologies, Inc. - 14, 19.64IneoquestoIngenio, LLC - 14, 19.57IngenioInikoa Medical, Ic. - 14, 20.5Inikoa Medical IcInnoblative Designs, Inc. - 14, 15.29Innoblative Desig…IncellDx, Inc. - 14, 14.43Incelldx
Incelldx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Incelldx's grants concentrate

IncellDx, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 64.3% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2016. By volume, Incelldx sits between Ikena Oncology, Inc. and Innoblative Designs, Inc..

Incelldx's three-year grant acceleration

IncellDx, Inc. shows 5 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at IncellDx's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows IncellDx holds 14 patents at rank #19,921, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near IncellDx

By rank, the assignees closest to #19,921 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in IncellDx's primary technology class.

Incelldx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 45% higher than 55% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201620182019202020212022202320242025 2
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
IncellDx, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 1 7.1%
2018 1 7.1%
2019 2 14.3%
2020 2 14.3%
2021 1 7.1%
2022 1 7.1%
2023 2 14.3%
2024 2 14.3%
2025partial year 2 14.3%

Which technologies does IncellDx, Inc. patent most?

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

IncellDx, Inc.'s patent record in context - here's where to go next.

  • IncellDx, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 64.3% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #19,896 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare IncellDx, Inc. against Ikena Oncology, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 36.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.